Literature DB >> 5429106

Miosis during L-dopa therapy.

A S Spiers, D B Calne, P M Fayers.   

Abstract

The pupillary diameter of 11 patients with Parkinson's disease was significantly decreased four hours after ingestion of L-dopa. It is suggested that this miosis may be caused by diminished noradrenaline output at sympathetic nerve endings, or alternatively by an action on the central nervous system.

Entities:  

Mesh：

Substances：

Year:  1970        PMID： 5429106      PMCID： PMC1700778          DOI： 10.1136/bmj.2.5710.639

Source DB:  PubMed          Journal:  Br Med J        ISSN： 0007-1447


  15 in total

1.  Modification of Parkinsonism--chronic treatment with L-dopa.

Authors:  G C Cotzias; P S Papavasiliou; R Gellene
Journal:  N Engl J Med       Date:  1969-02-13       Impact factor: 91.245

2.  Effects of L-dopa in Parkinson's disease.

Authors:  R B Godwin-Austen; E B Tomlinson; C C Frears; H W Kok
Journal:  Lancet       Date:  1969-07-26       Impact factor: 79.321

3.  L-dopa in idiopathic parkinsonism.

Authors:  D B Calne; G M Stern; A S Spiers; D R Laurence
Journal:  Lancet       Date:  1969-11-08       Impact factor: 79.321

4.  L-dopa in postencephalitic parkinsonism.

Authors:  D B Calne; G M Stern; D R Laurence; J Sharkey; P Armitage
Journal:  Lancet       Date:  1969-04-12       Impact factor: 79.321

5.  Mydriatic responses to sympathomimetic amines in patients treated with L-dopa.

Authors:  R B Godwin-Austen; N A Lind; P Turner
Journal:  Lancet       Date:  1969-11-15       Impact factor: 79.321

6.  Parkinsonism and DOPA.

Authors:  G C Cotzias; P S Papavasiliou; R Gellene; R B Aronson
Journal:  Trans Assoc Am Physicians       Date:  1968

7.  The potential role of dopamine in the treatment of shock.

Authors:  L I Goldberg; R C Talley; J L McNay
Journal:  Prog Cardiovasc Dis       Date:  1969-07       Impact factor: 8.194

8.  Treatment of parkinsonism with levodopa.

Authors:  M D Yahr; R C Duvoisin; M J Schear; R E Barrett; M M Hoehn
Journal:  Arch Neurol       Date:  1969-10

9.  The release of 3H-dopamine from the isolated rabbit ileum.

Authors:  G G Collins; G B West
Journal:  Br J Pharmacol       Date:  1968-11       Impact factor: 8.739

10.  L-Dopa (L-3,4-dihydroxyphenylanine)--its clinical effects in parkinsonism.

Authors:  M D Yahr; R C Duvoisin; M M Hoehn; M J Schear; R E Barrett
Journal:  Trans Am Neurol Assoc       Date:  1968
View more
  5 in total

Review 1.  Levodopa: a review of its pharmacological properties and therapeutic use with particular reference to Parkinsonism.

Authors:  R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1971       Impact factor: 9.546

2.  Action of thymoxamine on mydriasis induced by levodopa and dopamine.

Authors:  A S Spiers; D B Calne; S D Vakil; T M French
Journal:  Br Med J       Date:  1971-05-22

3.  Incidence of side effects from levodopa during the introduction of treatment.

Authors:  R B Godwin-Austen; C C Frears; S Bergmann
Journal:  Br Med J       Date:  1971-01-30

4.  Visual symptoms in Parkinson's disease.

Authors:  R A Armstrong
Journal:  Parkinsons Dis       Date:  2011-05-25

5.  Decreased Palpebral Fissure in Patients with Parkinson's Disease.

Authors:  Marina Sanchez Abraham; Gonzalo Gomez Arevalo; Silvia S Garcia; Gabriel Mizraji; Anabel Chade; Oscar Gershanik
Journal:  Mov Disord Clin Pract       Date:  2016-03-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.